GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for RADICAL PC

RADICAL PC

Official Title

The Role of Androgen Deprivation Therapy In CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)

Status

Ongoing

Overview

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Study Design

RADICAL PC1 is observational and RADICAL PC2 is a randomized-controlled trial.

Primary Endpoint

The primary objective of RADICAL PC1 is to determine the prevalence of cardiovascular risk factors and disease, and the incidence of major adverse cardiovascular events in men with prostate cancer and in particular men treated with Androgen Deprivation Therapy.

The primary objective of RADICAL PC2 is to determine whether a systematic cardiovascular and lifestyle risk factor modification strategy reduces the risk of major adverse cardiovascular events in men with a new diagnosis of prostate cancer or who are commencing Androgen Deprivation Therapy for the first time.

Number of Patients

6000

Number of Sites

20

Number of Countries

1

Study Period

2015-2020

Principal Investigator

Dr. Jehonathan Pinthus

Program Manager

Shirley Pettit

Research Coordinator

Kayla Pohl

Collaborators

Prostate Cancer Canada